On September 10, Cooper fell 19.28% in regular trading, trading at $52.705/share, with turnover of $66.17 million, as multiple headwinds converged to trigger heavy selling pressure.

The decline was driven by a confluence of negative catalysts. Cooper reported fiscal Q3 adjusted EPS of $1.15, beating the $1.12 consensus, but revenue of $1.066 billion fell short of the $1.098 billion estimate. More critically, the company slashed its full-year fiscal 2026 guidance, now expecting revenue of $4.23 billion to $4.25 billion versus the prior range of $4.29 billion to $4.32 billion, and adjusted EPS of $4.51 to $4.55, down from the earlier $4.58 to $4.66 range — both well below analyst expectations of $4.31 billion and $4.63, respectively. Net income attributable to shareholders plunged 72.45% year-over-year to just $52.9 million.

Additionally, the company concluded its strategic review of CooperSurgical, opting to retain the business after deeming acquisition offers inadequate for shareholders — disappointing market expectations of a potential divestiture. Analysts responded swiftly: Baird downgraded the stock to Neutral from Outperform, cutting its target to $61 from $85, while JPMorgan lowered its target to $58 from $71, citing U.S. channel destocking pressures on the CooperVision segment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)